2026/01/27 更新

写真a

コンドウ　ヒロヤ
近藤　宏也
KONDO HIROYA
所属
医歯薬学域 助教（特任）
職名
助教（特任）
外部リンク

学位

  • 医学博士 （ 2025年9月   岡山大学 ）

  • 学士（医学） （ 2014年3月   岡山大学 ）

研究キーワード

  • 骨肉腫

  • 骨転移

  • 腫瘍微小環境

  • リハビリテーション

  • 整形外科

  • 細胞外小胞

  • 骨軟部腫瘍

  • 腫瘍関連マクロファージ

学歴

  • 岡山大学   Graduate School of Medicine , Dentistry and Pharmaceutical Sciences  

    2018年4月 - 2025年9月

    　 詳細を見る

    国名： 日本国

    researchmap

  • 岡山大学   Medical School   Faculty of Medicine

    2008年4月 - 2014年3月

    　 詳細を見る

    国名： 日本国

    researchmap

経歴

  • 岡山大学学術研究院医歯薬学域   運動器医療材料開発講座   助教

    2025年4月 - 現在

    　 詳細を見る

  • 国立研究開発法人国立がん研究センター   骨軟部腫瘍 リハビリテーション科   任意研修生

    2025年4月 - 現在

    　 詳細を見る

  • 国立研究開発法人国立がん研究センター   骨軟部腫瘍 リハビリテーション科   医員

    2024年4月 - 2025年3月

    　 詳細を見る

  • 国立研究開発法人国立がん研究センター   骨軟部腫瘍 リハビリテーション科   レジデント

    2023年4月 - 2024年3月

    　 詳細を見る

  • 四国がんセンター   骨軟部腫瘍・整形外科 リハビリテーション科   医員

    2022年4月 - 2023年3月

    　 詳細を見る

    国名：日本国

    researchmap

  • 岡山大学病院   整形外科   医員

    2019年4月 - 2022年3月

    　 詳細を見る

  • 岡山大学病院   整形外科   医員

    2018年4月 - 2018年11月

    　 詳細を見る

▼全件表示

委員歴

  • 日本臨床腫瘍研究グループ（JCOG）   若手の会委員  

    2025年4月 - 現在   

    　 詳細を見る

 

論文

  • Subtype-specific characteristics and outcomes of liposarcoma: A population-based study using Japan's National Cancer Registry.

    Hiroya Kondo, Koichi Ogura, Chigusa Morizane, Tomoyuki Satake, Shintaro Iwata, Yu Toda, Shudai Muramatsu, Toshiyuki Takemori, Eisuke Kobayashi, Takahiro Higashi, Akira Kawai

    Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association   2026年1月

    　詳細を見る

    担当区分：筆頭著者   記述言語：英語   掲載種別：研究論文（学術雑誌）  

    BACKGROUND: Liposarcoma demonstrates significant biological and clinical heterogeneity across subtypes, yet optimal treatment strategies remain controversial. We evaluated subtype-specific treatment outcomes and hospital volume effects using population-based registry data. METHODS: We conducted a population-based cohort study analyzing 6,678 patients with liposarcoma diagnosed between 2016 and 2019 from the Japanese National Cancer Registry. Subtype-specific clinical characteristics, treatment patterns, and survival outcomes were evaluated using Cox regression and Kaplan-Meier methods. Propensity score matching was performed to assess radiotherapy and chemotherapy effectiveness while controlling for confounding variables. RESULTS: Well-differentiated liposarcoma was most common (46.2 %), followed by dedifferentiated (27.8 %), myxoid (10.8 %), and pleomorphic (3.2 %) subtypes. Myxoid liposarcomas predominantly affected patients aged <60 years (63.8 %). Multivariate analysis identified male sex (HR 1.264, p = 0.008), older age (HR 3.307, p < 0.001), retroperitoneal location (HR 1.861, p < 0.001), distant disease (HR 6.091, p < 0.001), and treatment at low-volume hospitals (HR 1.381, p = 0.001) as independent poor prognostic factors. Propensity score-matched analysis demonstrated improved survival with radiotherapy in dedifferentiated liposarcomas (3-year survival: 76.5 % vs. 66.1 %, p = 0.022) and with chemotherapy in pleomorphic liposarcomas (3-year survival: 87.5 % vs. 68.8 %, p = 0.038). CONCLUSIONS: Treatment efficacy varies significantly across liposarcoma subtypes, with potential survival benefits of radiotherapy in dedifferentiated subtypes and chemotherapy in pleomorphic subtypes. These findings support subtype-guided treatment approaches and suggest benefits of centralized care for optimal therapy implementation.

    DOI： 10.1016/j.jos.2025.12.011

    PubMed

    researchmap

  • Osteosarcoma cell-derived CCL2 facilitates lung metastasis via accumulation of tumor-associated macrophages. 国際誌

    Hiroya Kondo, Hiroshi Tazawa, Tomohiro Fujiwara, Aki Yoshida, Miho Kure, Koji Demiya, Nobuhiko Kanaya, Toshiaki Hata, Koji Uotani, Joe Hasei, Toshiyuki Kunisada, Shunsuke Kagawa, Yusuke Yoshioka, Toshifumi Ozaki, Toshiyoshi Fujiwara

    Cancer immunology, immunotherapy : CII   74 ( 7 )   193 - 193   2025年5月

    　詳細を見る

    担当区分：筆頭著者   記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1007/s00262-025-04051-x

    Web of Science

    PubMed

    researchmap

  • The impact of adjuvant therapy in extraskeletal osteosarcoma: A propensity score-matched analysis of 226 cases from the bone and Soft Tissue Tumor Registry in Japan. 国際誌

    Hiroya Kondo, Koichi Ogura, Akira Kawai

    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology   51 ( 6 )   110118 - 110118   2025年5月

    　詳細を見る

    担当区分：筆頭著者   記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1016/j.ejso.2025.110118

    Web of Science

    PubMed

    researchmap

  • Chondrosarcoma in Japan: an analytic study using population-based National Cancer Registry. 国際誌

    Hiroya Kondo, Koichi Ogura, Chigusa Morizane, Tomoyuki Satake, Shintaro Iwata, Yu Toda, Shudai Muramatsu, Toshiyuki Takemori, Eisuke Kobayashi, Takahiro Higashi, Akira Kawai

    Japanese journal of clinical oncology   55 ( 5 )   490 - 497   2025年2月

    　詳細を見る

    担当区分：筆頭著者   記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1093/jjco/hyaf024

    Web of Science

    PubMed

    researchmap

  • p53-armed oncolytic virotherapy induces abscopal effect in osteosarcoma by promoting immunogenic cell death. 国際誌

    Koji Demiya, Hiroshi Tazawa, Hiroya Kondo, Miho Kure, Yusuke Mochizuki, Tadashi Komatsubara, Aki Yoshida, Koji Uotani, Joe Hasei, Tomohiro Fujiwara, Toshiyuki Kunisada, Yasuo Urata, Shunsuke Kagawa, Toshifumi Ozaki, Toshiyoshi Fujiwara

    Molecular therapy. Oncology   32 ( 3 )   200845 - 200845   2024年9月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1016/j.omton.2024.200845

    Web of Science

    PubMed

    researchmap

  • CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment 国際誌

    Tomohiro Fujiwara, Mohamed A. Yakoub, Andrew Chandler, Alexander Christ, Guangli Yang, Ouathek Ouerfelli, Vinagolu K. Rajasekhar, Aki Yoshida, Hiroya Kondo, Toshiaki Hata, Hiroshi Tazawa, Yildirim Dogan, Malcolm A.S. Moore, Toshiyoshi Fujiwara, Toshifumi Ozaki, Ed Purdue, John Healey

    Molecular Cancer Therapeutics   20 ( 8 )   1388 - 1399   2021年8月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    <jats:title>Abstract</jats:title>
    <jats:p>Colony-stimulating factor 1 (CSF1) is a primary regulator of the survival, proliferation, and differentiation of monocyte/macrophage that sustains the protumorigenic functions of tumor-associated macrophages (TAMs). Considering current advances in understanding the role of the inflammatory tumor microenvironment, targeting the components of the sarcoma microenvironment, such as TAMs, is a viable strategy. Here, we investigated the effect of PLX3397 (pexidartinib) as a potent inhibitor of the CSF1 receptor (CSF1R). PLX3397 was recently approved by the Food and Drug Administration (FDA) to treat tenosynovial giant cell tumor and reprogram TAMs whose infiltration correlates with unfavorable prognosis of sarcomas. First, we confirmed by cytokine arrays of tumor-conditioned media (TCM) that cytokines including CSF1 are secreted from LM8 osteosarcoma cells and NFSa fibrosarcoma cells. The TCM, like CSF1, stimulated ERK1/2 phosphorylation in bone marrow–derived macrophages (BMDMs), polarized BMDMs toward an M2 (TAM-like) phenotype, and strikingly promoted BMDM chemotaxis. In vitro administration of PLX3397 suppressed pERK1/2 stimulation by CSF1 or TCM, and reduced M2 polarization, survival, and chemotaxis in BMDMs. Systemic administration of PLX3397 to the osteosarcoma orthotopic xenograft model significantly suppressed the primary tumor growth and lung metastasis, and thus improved metastasis-free survival. PLX3397 treatment concurrently depleted TAMs and FOXP3+ regulatory T cells and, surprisingly, enhanced infiltration of CD8+ T cells into the microenvironments of both primary and metastatic osteosarcoma sites. Our preclinical results show that PLX3397 has strong macrophage- and T-cell–modulating effects that may translate into cancer immunotherapy for bone and soft-tissue sarcomas.</jats:p>

    DOI： 10.1158/1535-7163.mct-20-0591

    PubMed

    researchmap

  • Telomerase-specific oncolytic immunotherapy for promoting efficacy of PD-1 blockade in osteosarcoma 国際誌

    Yusuke Mochizuki, Hiroshi Tazawa, Koji Demiya, Miho Kure, Hiroya Kondo, Tadashi Komatsubara, Kazuhisa Sugiu, Joe Hasei, Aki Yoshida, Toshiyuki Kunisada, Yasuo Urata, Shunsuke Kagawa, Toshifumi Ozaki, Toshiyoshi Fujiwara

    Cancer Immunology, Immunotherapy   70 ( 5 )   1405 - 1417   2021年5月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    Immune checkpoint inhibitors including anti-programmed cell death 1 (PD-1) antibody have recently improved clinical outcome in certain cancer patients; however, osteosarcoma (OS) patients are refractory to PD-1 blockade. Oncolytic virotherapy has emerged as novel immunogenic therapy to augment antitumor immune response. We developed a telomerase-specific replication-competent oncolytic adenovirus OBP-502 that induces lytic cell death via binding to integrins. In this study, we assessed the combined effect of PD-1 blockade and OBP-502 in OS cells. The expression of coxsackie and adenovirus receptor (CAR), integrins αvβ3 and αvβ5, and programmed cell death ligand 1 (PD-L1) was analyzed in two murine OS cells (K7M2, NHOS). The cytopathic activity of OBP-502 in both cells was analyzed using the XTT assay. OBP-502-induced immunogenic cell death was assessed by analyzing the level of extracellular ATP and high-mobility group box protein B1 (HMGB1). Subcutaneous tumor models for K7M2 and NHOS cells were used to evaluate the antitumor effect and number of tumor-infiltrating CD8+ cells in combination therapy. K7M2 and NHOS cells showed high expression of integrins αvβ3 and αvβ5, but not CAR. OBP-502 significantly suppressed the viability of both cells, in which PD-L1 expression and the release of ATP and HMGB1 were significantly increased. Intratumoral injection of OBP-502 significantly augmented the efficacy of PD-1 blockade on subcutaneous K2M2 and NHOS tumor models via enhancement of tumor-infiltrating CD8+  T cells. Our results suggest that telomerase-specific oncolytic virotherapy is a promising antitumor strategy to promote the efficacy of PD-1 blockade in OS.

    DOI： 10.1007/s00262-020-02774-7

    PubMed

    researchmap

  • P53-Armed Oncolytic Virotherapy Promotes the Efficacy of PD1 Blockade in Murine Osteosarcoma Tumors. 国際誌

    Miho Kure, Hiroshi Tazawa, Koji Demiya, Hiroya Kondo, Yusuke Mochizuki, Tadashi Komatsubara, Aki Yoshida, Koji Uotani, Joe Hasei, Tomohiro Fujiwara, Toshiyuki Kunisada, Yasuo Urata, Shunsuke Kagawa, Toshifumi Ozaki, Toshiyoshi Fujiwara

    Anticancer research   46 ( 1 )   69 - 84   2026年1月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.21873/anticanres.17924

    Web of Science

    PubMed

    researchmap

  • Analysis of comprehensive genomic profiling test for Ewing sarcoma in pediatric patients and adults using the nationwide clinical and genomic database in Japan 国際誌

    Satoshi Kamio, Koichi Ogura, Yoshiyuki Suehara, Rina Kitada, Masachika Ikegami, Kuniko Sunami, Takafumi Koyama, Noboru Yamamoto, Seiji Shimomura, Hiroya Kondo, Toshiyuki Takemori, Shuhei Osaki, Eisuke Kobayashi, Shintaro Iwata, Shinji Kohsaka, Akira Kawai

    Japanese Journal of Clinical Oncology   56 ( 1 )   33 - 39   2025年11月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1093/jjco/hyaf174

    Web of Science

    PubMed

    researchmap

  • Epidemiology and prognosis of malignant peripheral nerve sheath tumor (MPNST) in Japan: A population-based analysis using the national cancer registry.

    Shudai Muramatsu, Koichi Ogura, Chigusa Morizane, Tomoyuki Satake, Shintaro Iwata, Eisuke Kobayashi, Takahiro Higashi, Yu Toda, Toshiyuki Takemori, Hiroya Kondo, Akira Kawai

    Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association   2025年10月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    BACKGROUND: The national epidemiology of malignant peripheral nerve sheath tumor (MPNST) remains underexplored. We analyzed Japanese domestic statistics for MPNST using the National Cancer Registry (NCR), a population-based database launched in 2016. METHODS: We analyzed 837 MPNST cases diagnosed between 2016 and 2019, comparing them with 22,685 non-MPNST soft tissue sarcomas. We assessed demographics, treatment, and survival using Kaplan-Meier and Cox proportional hazards models. RESULTS: The age-adjusted incidence of MPNST in Japan was 0.13 per 100,000. Unlike other sarcomas, MPNST showed a balanced sex ratio and a relatively higher proportion of adolescent and young adult (AYA) patients (18.5 % vs. 10.7 %, p < 0.001). Most MPNSTs (87.4 %) originated from the skin and soft tissues. The 3-year survival rate for MPNST patients (53.0 %) was lower than that for other sarcomas (64.3 %, p < 0.001). Surgery was associated with longer survival (hazard ratio [HR]: 2.09; p < 0.001), while no clear benefit was observed for chemotherapy or radiotherapy. Radiotherapy was more frequently used in MPNST patients (21.1 % vs. 15.6 %, p < 0.001), likely reflecting a selection bias towards non-surgical cases. CONCLUSIONS: This is the first study to analyze the national epidemiology and prognosis of MPNST in a socio-economically homogeneous, single ethnic group. MPNST primarily affected the skin and soft tissues, with a higher incidence in the AYA group. Surgery was associated with better outcomes, whereas chemotherapy and radiotherapy implied poorer prognosis owing to selection bias for unresectable cases. The NCR provides a valuable model for research on rare diseases in homogeneous populations.

    DOI： 10.1016/j.jos.2025.09.007

    PubMed

    researchmap

  • Utility of Same-Modality, Cross-Domain Transfer Learning for Malignant Bone Tumor Detection on Radiographs: A Multi-Faceted Performance Comparison with a Scratch-Trained Model. 国際誌

    Joe Hasei, Ryuichi Nakahara, Yujiro Otsuka, Koichi Takeuchi, Yusuke Nakamura, Kunihiro Ikuta, Shuhei Osaki, Hironari Tamiya, Shinji Miwa, Shusa Ohshika, Shunji Nishimura, Naoaki Kahara, Aki Yoshida, Hiroya Kondo, Tomohiro Fujiwara, Toshiyuki Kunisada, Toshifumi Ozaki

    Cancers   17 ( 19 )   2025年9月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.3390/cancers17193144

    Web of Science

    PubMed

    researchmap

  • Epidemiology and Outcomes of Retroperitoneal Sarcoma: An Analysis of the Population-Based Cancer Registry in Japan 2016-2019. 国際誌

    Toshiyuki Takemori, Koichi Ogura, Chigusa Morizane, Tomoyuki Satake, Shintaro Iwata, Yu Toda, Shudai Muramatsu, Hiroya Kondo, Eisuke Kobayashi, Takahiro Higashi, Akira Kawai

    Journal of surgical oncology   132 ( 6 )   1106 - 1115   2025年9月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1002/jso.70074

    Web of Science

    PubMed

    researchmap

  • Advances in liquid biopsy for bone and soft-tissue sarcomas.

    Yilang Wang, Tomohiro Fujiwara, Takanao Kurozumi, Teruhiko Ando, Takahiko Ishimaru, Hiroya Kondo, Eiji Nakata, Toshiyuki Kunisada, Toshifumi Ozaki

    International journal of clinical oncology   30 ( 9 )   1722 - 1733   2025年7月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1007/s10147-025-02813-2

    Web of Science

    PubMed

    researchmap

  • Significance of Regional Lymph Node Dissection in Patients With Clear Cell Sarcoma and Epithelioid Sarcoma 国際誌

    Toshiyuki Takemori, Eisuke Kobayashi, Shudai Muramatsu, Shintaro Iwata, Koichi Ogura, Shuhei Osaki, Suguru Fukushima, Seiji Shimomura, Hiroya Kondo, Satoshi Kamio, Akira Kawai

    JBJS Open Access   10 ( 3 )   2025年7月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.2106/JBJS.OA.25.00063

    Web of Science

    PubMed

    researchmap

  • Incidence and age- and site-specific characteristics of osteosarcoma: a population-based study using National Cancer Registry 2016-2019. 国際誌

    Koichi Ogura, Chigusa Morizane, Tomoyuki Satake, Shintaro Iwata, Yu Toda, Shudai Muramatsu, Toshiyuki Takemori, Hiroya Kondo, Eisuke Kobayashi, Ayumu Arakawa, Chitose Ogawa, Yoko Katoh, Takahiro Higashi, Akira Kawai

    Japanese journal of clinical oncology   55 ( 9 )   1037 - 1045   2025年6月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1093/jjco/hyaf086

    Web of Science

    PubMed

    researchmap

  • Establishment and characterization of NCC-MLPS4-C1: a novel patient-derived cell line of myxoid liposarcoma.

    Julia Osaki, Rei Noguchi, Takuya Ono, Yuki Adachi, Shuhei Iwata, Yomogi Shiota, Hiroya Kondo, Koichi Ogura, Shogo Nishino, Akihiko Yoshida, Akira Kawai, Tadashi Kondo

    Human cell   38 ( 4 )   109 - 109   2025年5月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1007/s13577-025-01241-8

    Web of Science

    PubMed

    researchmap

  • Incidence and site specific characteristics of angiosarcoma in Japan using a population-based national cancer registry from 2016 to 2019. 国際誌

    Toshiyuki Takemori, Koichi Ogura, Chigusa Morizane, Tomoyuki Satake, Shintaro Iwata, Yu Toda, Shudai Muramatsu, Hiroya Kondo, Eisuke Kobayashi, Takahiro Higashi, Akira Kawai

    Scientific reports   15 ( 1 )   9960 - 9960   2025年3月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1038/s41598-025-94956-5

    Web of Science

    PubMed

    researchmap

  • Prognostic factors and management of elderly sarcoma in Japan: the population-based National Cancer Registry (NCR) in Japan.

    Yu Toda, Koichi Ogura, Chigusa Morizane, Tomoyuki Satake, Shintaro Iwata, Eisuke Kobayashi, Toshiyuki Takemori, Hiroya Kondo, Shudai Muramatsu, Takahiro Higashi, Akira Kawai

    International journal of clinical oncology   30 ( 5 )   1018 - 1032   2025年2月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1007/s10147-025-02719-z

    Web of Science

    PubMed

    researchmap

  • Statistics of chondrosarcoma in Japan: Report from the population-based cancer registry in Japan

    Hiroya Kondo, Koichi Ogura, Chigusa Morizane, Tomoyuki Satake, Shintaro Iwata, Yu Toda, Shudai Muramatsu, Toshiyuki Takemori, Eisuke Kobayashi, Takahiro Higashi, Akira Kawai

    CANCER SCIENCE   116   600 - 600   2025年1月

    　詳細を見る

    記述言語：英語  

    Web of Science

    researchmap

  • Prognostic Stratification of Standard Responders to Neoadjuvant Chemotherapy in Patients with Osteosarcoma Using 18F-FDG PET/CT Imaging. 国際誌

    Toshiyuki Takemori, Eisuke Kobayashi, Akihiko Yoshida, Ayumu Arakawa, Hiroya Kondo, Satoshi Kamio, Seiji Shimomura, Shuhei Osaki, Koichi Ogura, Shintaro Iwata, Chitose Ogawa, Akira Kawai, Kimiteru Ito

    JB & JS open access   10 ( 4 )   2025年

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    INTRODUCTION: We aimed to identify a new biomarker using 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) parameters to identify osteosarcoma patients with standard response after neoadjuvant chemotherapy (NAC). PATIENTS AND MATERIALS: Fifty-four patients with conventional osteosarcoma (age ≤39 years) were included in this study. All patients underwent 18F-FDG PET/CT before (PET1) and after NAC (PET2). We measured PET parameters, including maximum, average, and peak standardized uptake value (SUVmax, SUVave, and SUVpeak); metabolic tumor volume (MTV); and total lesion glycolysis (TLG). Their changes (ΔPET = PET2/PET1) were also examined. The patients were classified into 4 groups based on the histological tumor necrosis rate (TNR): G0 (<50%), G1 (50 to < 90%), G2 (90 to < 100%), and G3 (100%). G0 and G1 patients were enrolled in the standard responder (SR) group (n = 35), while G2 and G3 patients were enrolled in the good responder (GR) group (n = 19). We examined the correlation between changes in each 18F-FDG PET/CT parameter and TNR as well as overall survival (OS) and progression-free survival (PFS) among the 4 groups. In the SR group, the median value of ΔSUVmax was calculated and correlated with prognostic stratification. RESULTS: The changes in each PET parameter were correlated with TNR, with SUVpeak showing the strongest correlation. Moreover, in the SR group, there were no differences in OS or PFS between G0 and G1. Patients in the SR group were stratified into 2 groups according to the median ΔSUVmax value (0.62). Patients with ΔSUVmax < 0.62 had significantly better OS (P < 0.01) and PFS (P = 0.02) in comparison with patients with ΔSUVmax ≥ 0.62. In multivariate analyses, ΔSUVmax showed a correlation with OS in the SR group. DISCUSSION: This study revealed that ΔSUVmax may confirm the preoperative stratification of the prognosis be a predictive biomarker for patients in the SR group. Moreover, the preoperative identification of patients with a worse prognosis in the SR group has a significant impact on improving the clinical outcomes of patients with osteosarcoma. LEVEL OF EVIDENCE: Prognostic studies, Level III. See Instructions for Authors for a complete description of levels of evidence.

    DOI： 10.2106/JBJS.OA.25.00133

    PubMed

    researchmap

  • Establishment and characterization of NCC-GCTB10-C1: a novel cell line derived from a patient with recurrent giant cell tumor of bone.

    Yuki Adachi, Rei Noguchi, Julia Osaki, Takuya Ono, Taro Akiyama, Hiroya Kondo, Eisuke Kobayashi, Naoki Kojima, Akihiko Yoshida, Hideki Yokoo, Akira Kawai, Tadashi Kondo

    Human cell   38 ( 1 )   29 - 29   2024年12月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1007/s13577-024-01153-z

    Web of Science

    PubMed

    researchmap

  • Clear cell sarcoma in Japan: an analysis of the population-based cancer registry in Japan. 国際誌

    Toshiyuki Takemori, Koichi Ogura, Chigusa Morizane, Tomoyuki Satake, Shintaro Iwata, Yu Toda, Shudai Muramatsu, Hiroya Kondo, Eisuke Kobayashi, Takahiro Higashi, Akira Kawai

    Japanese journal of clinical oncology   54 ( 12 )   1281 - 1287   2024年12月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1093/jjco/hyae112

    Web of Science

    PubMed

    researchmap

  • Soft-tissue sarcoma in Japan: National Cancer Registry-based analysis from 2016 to 2019. 国際誌

    Koichi Ogura, Chigusa Morizane, Tomoyuki Satake, Shintaro Iwata, Yu Toda, Shudai Muramatsu, Toshiyuki Takemori, Hiroya Kondo, Eisuke Kobayashi, Yoko Katoh, Takahiro Higashi, Akira Kawai

    Japanese journal of clinical oncology   54 ( 11 )   1150 - 1157   2024年7月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1093/jjco/hyae088

    Web of Science

    PubMed

    researchmap

  • Comparison of clinical outcome between surgical treatment and particle beam therapy for pelvic bone sarcomas: A retrospective multicenter study in Japan.

    Toshiyuki Takemori, Hitomi Hara, Teruya Kawamoto, Naomasa Fukase, Ryoko Sawada, Shuichi Fujiwara, Ikuo Fujita, Takuya Fujimoto, Masayuki Morishita, Shunsuke Yahiro, Tomohiro Miyamoto, Masanori Saito, Jun Sugaya, Katsuhiro Hayashi, Hiroyuki Kawashima, Tomoaki Torigoe, Tomoki Nakamura, Hiroya Kondo, Toru Wakamatsu, Munenori Watanuki, Munehisa Kito, Satoshi Tsukushi, Akihito Nagano, Hidetatsu Outani, Shunichi Toki, Shunji Nishimura, Hiroshi Kobayashi, Itsuo Watanabe, Yusuke Demizu, Ryohei Sasaki, Takumi Fukumoto, Tomoyuki Matsumoto, Ryosuke Kuorda, Toshihiro Akisue

    Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association   30 ( 3 )   523 - 528   2024年7月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1016/j.jos.2024.06.007

    Web of Science

    PubMed

    researchmap

  • Fluorescence-guided assessment of bone and soft-tissue sarcomas for predicting the efficacy of telomerase-specific oncolytic adenovirus. 国際誌

    Koji Uotani, Hiroshi Tazawa, Joe Hasei, Tomohiro Fujiwara, Aki Yoshida, Yasuaki Yamakawa, Toshinori Omori, Kazuhisa Sugiu, Tadashi Komatsubara, Hiroya Kondo, Takuya Morita, Masahiro Kiyono, Suguru Yokoo, Toshiaki Hata, Toshiyuki Kunisada, Ken Takeda, Yasuo Urata, Toshiyoshi Fujiwara, Toshifumi Ozaki

    PloS one   19 ( 2 )   e0298292   2024年

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    Bone and soft-tissue sarcomas are rare malignancies with histological diversity and tumor heterogeneity, leading to the lack of a common molecular target. Telomerase is a key enzyme for keeping the telomere length and human telomerase reverse transcriptase (hTERT) expression is often activated in most human cancers, including bone and soft-tissue sarcomas. For targeting of telomerase-positive tumor cells, we developed OBP-301, a telomerase-specific replication-competent oncolytic adenovirus, in which the hTERT promoter regulates adenoviral E1 gene for tumor-specific viral replication. In this study, we present the diagnostic potential of green fluorescent protein (GFP)-expressing oncolytic adenovirus OBP-401 for assessing virotherapy sensitivity using bone and soft-tissue sarcomas. OBP-401-mediated GFP expression was significantly associated with the therapeutic efficacy of OBP-401 in human bone and soft-tissue sarcomas. In the tumor specimens from 68 patients, malignant and intermediate tumors demonstrated significantly higher expression levels of coxsackie and adenovirus receptor (CAR) and hTERT than benign tumors. OBP-401-mediated GFP expression was significantly increased in malignant and intermediate tumors with high expression levels of CAR and hTERT between 24 and 48 h after infection. Our results suggest that the OBP-401-based GFP expression system is a useful tool for predicting the therapeutic efficacy of oncolytic virotherapy on bone and soft-tissue sarcomas.

    DOI： 10.1371/journal.pone.0298292

    PubMed

    researchmap

  • Clinical Outcome of Patients with Pelvic and Retroperitoneal Bone and Soft Tissue Sarcoma: A Retrospective Multicenter Study in Japan 国際誌

    Toshiyuki Takemori, Teruya Kawamoto, Hitomi Hara, Naomasa Fukase, Shuichi Fujiwara, Ikuo Fujita, Takuya Fujimoto, Masayuki Morishita, Kazumichi Kitayama, Shunsuke Yahiro, Tomohiro Miyamoto, Masanori Saito, Jun Sugaya, Katsuhiro Hayashi, Hiroyuki Kawashima, Tomoaki Torigoe, Tomoki Nakamura, Hiroya Kondo, Toru Wakamatsu, Munenori Watanuki, Munehisa Kito, Satoshi Tsukushi, Akihito Nagano, Hidetatsu Outani, Shunichi Toki, Shunji Nishimura, Hiroshi Kobayashi, Itsuo Watanabe, Yusuke Demizu, Ryohei Sasaki, Takumi Fukumoto, Takahiro Niikura, Ryosuke Kuroda, Toshihiro Akisue

    Cancers   14 ( 12 )   2022年6月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    <jats:p>This study aimed to retrospectively analyze the clinical outcomes of patients with pelvic and retroperitoneal bone and soft tissue sarcoma (BSTS). Overall, 187 patients with BSTS in the pelvis and retroperitoneal region treated at 19 specialized sarcoma centers in Japan were included. The prognostic factors related to overall survival (OS), local control (LC), and progression-free survival (PFS) were evaluated. The 3-year OS and LC rates in the 187 patients were 71.7% and 79.1%, respectively. The 3-year PFS in 166 patients without any distant metastases at the time of primary tumor diagnosis was 48.6%. Osteosarcoma showed significantly worse OS and PFS than other sarcomas of the pelvis and retroperitoneum. In the univariate analyses, larger primary tumor size, soft tissue tumor, distant metastasis at the time of primary tumor diagnosis, P2 location, chemotherapy, and osteosarcoma were poor prognostic factors correlated with OS. Larger primary tumor size, higher age, soft tissue tumor, chemotherapy, and osteosarcoma were poor prognostic factors correlated with PFS in patients without any metastasis at the initial presentation. Larger primary tumor size was the only poor prognostic factor correlation with LC. This study has clarified the epidemiology and prognosis of patients with pelvic and retroperitoneal BSTS in Japan.</jats:p>

    DOI： 10.3390/cancers14123023

    PubMed

    researchmap

  • Soft-tissue sarcoma in adolescents and young adults

    Toshiyuki Kunisada, Eiji Nakata, Tomohiro Fujiwara, Ako Hosono, Shota Takihira, Hiroya Kondo, Toshifumi Ozaki

    International Journal of Clinical Oncology   28 ( 1 )   1 - 11   2022年1月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：Springer Science and Business Media LLC  

    Soft-tissue sarcoma is a rare cancer that accounts for approximately 1% of all malignant tumors. Although they occur in various age groups, soft-tissue sarcomas account for 8% of all malignant tumors developing in adolescents and young adults, suggesting that they are not rare in this age group. This study aimed to evaluate the clinical and pathological characteristics of soft-tissue sarcoma in adolescents and young adults. According to the Bone and Soft-Tissue Tumor Registry in Japan, myxoid liposarcoma is the most common type of soft-tissue sarcoma found in adolescents and young adults; alveolar soft part sarcoma, extraskeletal Ewing sarcoma, epithelioid sarcoma, clear cell sarcoma and synovial sarcoma occur predominantly in this age group among soft-tissue sarcomas. The analysis based on this registry demonstrated that age was not a prognostic factor for poor survival of soft-tissue sarcoma, although the prognosis in adolescents and young adults was better than that in older patients in the US and Scandinavia. Adolescent and young adult patients with soft-tissue sarcoma have age-specific problems, and a multidisciplinary approach to physical, psychological, and social issues is necessary to improve the management of these young patients both during and after treatment.

    DOI： 10.1007/s10147-022-02119-7

    PubMed

    researchmap

    その他リンク： https://link.springer.com/article/10.1007/s10147-022-02119-7/fulltext.html

  • Oncolytic virotherapy reverses chemoresistance in osteosarcoma by suppressing MDR1 expression 国際誌

    Kazuhisa Sugiu, Hiroshi Tazawa, Joe Hasei, YASUAKI YAMAKAWA, Toshinori Omori, Tadashi Komatsubara, Yusuke Mochizuki, Hiroya Kondo, Shuhei Osaki, Tomohiro Fujiwara, Aki Yoshida, Toshiyuki Kunisada, Koji Ueda, Yasuo Urata, Shunsuke Kagawa, Toshifumi Ozaki, Toshiyoshi Fujiwara

    Cancer Chemotherapy and Pharmacology   88 ( 3 )   513 - 524   2021年9月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    BACKGROUND: Osteosarcoma (OS) is a malignant bone tumor primarily affecting children and adolescents. The prognosis of chemotherapy-refractory OS patients is poor. We developed a tumor suppressor p53-expressing oncolytic adenovirus (OBP-702) that exhibits antitumor effects against human OS cells. Here, we demonstrate the chemosensitizing effect of OBP-702 in human OS cells. MATERIALS AND METHODS: The in vitro and in vivo antitumor activities of doxorubicin (DOX) and OBP-702 were assessed using parental and DOX-resistant OS cells (U2OS, MNNG/HOS) and a DOX-resistant MNNG/HOS xenograft tumor model. RESULTS: DOX-resistant OS cells exhibited high multidrug resistant 1 (MDR1) expression, which was suppressed by OBP-702 or MDR1 siRNA, resulting in enhanced DOX-induced apoptosis. Compared to monotherapy, OBP-702 and DOX combination therapy significantly suppressed tumor growth in the DOX-resistant MNNG/HOS xenograft tumor model. CONCLUSION: Our results suggest that MDR1 is an attractive therapeutic target for chemoresistant OS. Tumor-specific virotherapy is thus a promising strategy for reversing chemoresistance in OS patients via suppression of MDR1 expression.

    DOI： 10.1007/s00280-021-04310-5

    PubMed

    researchmap

  • Role of Tumor-Associated Macrophages in Sarcomas 国際誌

    Tomohiro Fujiwara, John Healey, Koichi Ogura, Hiroya Kondo, Hiroya Kondo, Toshiaki Hata, Hiroshi Tazawa, Eiji Nakata, Toshiyuki Kunisada, Toshiyoshi Fujiwara, Toshifumi Ozaki, Toshifumi Ozaki

    Cancers   13 ( 5 )   2021年3月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    <jats:p>Sarcomas are complex tissues in which sarcoma cells maintain intricate interactions with their tumor microenvironment. Tumor-associated macrophages (TAMs) are a major component of tumor-infiltrating immune cells in the tumor microenvironment and have a dominant role as orchestrators of tumor-related inflammation. TAMs promote tumor growth and metastasis, stimulate angiogenesis, mediate immune suppression, and limit the antitumor activity of conventional chemotherapy and radiotherapy. Evidence suggests that the increased infiltration of TAMs and elevated expression of macrophage-related genes are associated with poor prognoses in most solid tumors, whereas evidence of this in sarcomas is limited. Based on these findings, TAM-targeted therapeutic strategies, such as inhibition of CSF-1/CSF-1R, CCL2/CCR2, and CD47/SIRPα, have been developed and are currently being evaluated in clinical trials. While most of the therapeutic challenges that target sarcoma cells have been unsuccessful and the prognosis of sarcomas has plateaued since the 1990s, several clinical trials of these strategies have yielded promising results and warrant further investigation to determine their translational benefit in sarcoma patients. This review summarizes the roles of TAMs in sarcomas and provides a rationale and update of TAM-targeted therapy as a novel treatment approach for sarcomas.</jats:p>

    DOI： 10.3390/cancers13051086

    PubMed

    researchmap

  • The Masquelet technique for septic arthritis of the small joint in the hands: Case reports 国際誌

    Taichi Saito, Tomoyuki Noda, Hiroya Kondo, Koji Demiya, Satoshi Nezu, Suguru Yokoo, Minami Matsuhashi, Takenori Uehara, Yasunori Shimamura, Masayuki Kodama, Toshifumi Ozaki

    Trauma Case Reports   25   100268 - 100268   2020年2月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    Septic arthritis in distal interphalangeal (DIP) joints sometimes occurs in association with mucous cysts or after the surgical treatment of mallet fingers. Recently, several studies have demonstrated the effectiveness of the Masquelet technique in the treatment of bone defects caused by trauma or infection. However, only few studies have reported the use of this technique for septic arthritis in small joints of the hand, and its effectiveness in treating septic arthritis in DIP joints remains unclear. We report the clinical and radiological outcomes of three patients who were treated with the Masquelet technique for septic arthritis in DIP joints. One patient had uncontrolled diabetes and another had rheumatoid arthritis treated with methotrexate and prednisolone. The first surgical stage involved thorough debridement of the infection site, including the middle and distal phalanx. We placed an external fixator from the middle to the distal phalanx and then packed the cavity of the DIP joint with antibiotic cement bead of polymethylmethacrylate (40 g) including 2 g of vancomycin and 200 mg of minocycline. At 4-6 weeks after the first surgical stage, the infection had cleared, and the second surgical stage was performed. The external fixator and cement bead were carefully removed while carefully preserving the surrounding osteo-induced membrane. The membrane was smooth and nonadherent to the cement block. In the second surgical stage, an autogenous bone graft was harvested from the iliac bone and inserted into the joint space, within the membrane. The bone graft, distal phalanx, and middle phalanx were fixed with Kirschner wires and/or a soft wire. Despite the high risk of infection, bone union was achieved in all patients without recurrence of infection. Although the Masquelet technique requires two surgeries, it can lead to favorable clinical and radiological outcomes for infected small joints of the hand.

    DOI： 10.1016/j.tcr.2019.100268

    PubMed

    researchmap

▼全件表示

書籍等出版物

  • 救急・当直必携!頼れる整形外傷ポケットマニュアル : 症例で学ぶ、初期診療の基本からコンサルトまで

    野田, 知之

    羊土社  2022年5月  （ ISBN:9784758123907 ）

    　詳細を見る

    総ページ数：277p   記述言語：日本語

    CiNii Books

    researchmap

MISC

▼全件表示

講演・口頭発表等

  • 【シンポジウム】大規模データベースから見えてくる 骨・軟部腫瘍診療の現況ー全国骨・軟部腫瘍登録を用いた骨・軟部腫瘍診療実態の現況

    第98回日本整形外科学会学術集会  2025年5月23日 

    　詳細を見る

    開催年月日： 2025年5月21日 - 2025年5月24日

    会議種別：シンポジウム・ワークショップ パネル（指名）  

    researchmap

  • Tumor cell disappearance following COVID-19 infection in a patient with pleomorphic spindle cell sarcoma: A case report

    Kondo Hiroya, Eisuke Kobayashi, Shuhei Osaki, Koichi Ogura, Shintaro Iwata, Akira Kawai

    CTOS 2024 Annual Meeting  2024年11月15日 

    　詳細を見る

    開催年月日： 2024年11月13日 - 2024年11月16日

    記述言語：英語   会議種別：ポスター発表  

    researchmap

  • Efficacy of plasma D-dimer screening for preoperative thrombosis and prevention of postoperative symptomatic PE in sarcoma patients: a retrospective observation study

    Hiroya Kondo, E. Kobayashi, S. Fukushima, S. Osaki, K. Ogura, S. Iwata, A. Kawai

    ESMO SARCOMA AND RARE CANCERS  2024年3月15日 

    　詳細を見る

    開催年月日： 2024年3月14日 - 2024年3月16日

    記述言語：英語   会議種別：ポスター発表  

    researchmap

  • 【シンポジウム】転移性骨肉腫は臓器指向性サイトカインの分泌を介して微小環境を変化させ前転移ニッチを形成する 招待

    近藤宏也

    第37回日本整形外科学会基礎学術集会  2022年10月13日 

    　詳細を見る

    開催年月日： 2022年10月13日 - 2022年10月14日

    記述言語：日本語   会議種別：シンポジウム・ワークショップ パネル（指名）  

    researchmap

  • Capsular repair with polypropylene mesh for wide resection of malignant proximal femoral tumors and prosthetic reconstruction: A case series

    Hiroya Kondo, Eiji Nakata, Shota Takihira, Miho Kure, Ryoji Joko, Joe hasei, Aki Yoshida, Toshiyuki Kunisada, Toshifumi Ozaki

    Asia Pacific Musculoskeletal Tumor Society Meeting 13th APMSTS MEETING  2021年4月21日 

    　詳細を見る

    記述言語：英語  

    researchmap

  • Transcription Factor Twist1 Affects On Expression Of Abc Transporters And Chemoresistance To Doxorubicin In Human Osteosarcoma Cells.

    Hiroya Kondo, Joe Hasei, Mahito Nakanishi, Shota Takihira, Miho Kure, Ryoji Joko, Koji Demiya, Suguru Yokoo, Eiji Nakata, Aki Yoshida, Toshiyuki Kunisada, Toshifumi Ozaki

    Orthopaedic Research Society 2020 ANNUAL MEETING  2020年11月20日 

    　詳細を見る

    記述言語：英語   会議種別：口頭発表（一般）  

    researchmap

  • The comparison of the inter-observer reliability between pre-revised and post-revised AO classification for proximal humeral fracture.

    Hiroya KONDO, Yasuaki YAMAKAWA, Takehiro UEHARA, Taichi SAITO, Kenta SAIGA, Yasunori SHIMAMURA, Tomoyuki NODA, Toshifumi OZAKI

    4th AO trauma Asia Pacific Scientific Congress  2019年5月24日 

    　詳細を見る

    記述言語：英語   会議種別：口頭発表（一般）  

    researchmap

  • A case report of Herbert classification type B4 scahoid fracture (trans-scaphoid perilunate fracture dislocation)

    Hiroya Kondo, Takeshi Doi, Shimamura Yasunori

    AO Trauma Asia Pacific Clinical Rearch Forum  2017年6月17日 

    　詳細を見る

    会議種別：口頭発表（一般）  

    researchmap

▼全件表示

受賞

  • 第145回中部日本整形外科災害外科学会学会奨励賞

    中部日本整形外科災害外科学会   臓器指向性ケモカインを介した骨肉腫の肺転移メカニズムの解明

    　詳細を見る

共同研究・競争的資金等の研究

  • 肉腫における体液分子診断技術の統合的開発と循環分子の新規治療標的としての検証

    研究課題/領域番号：23K24461  2022年04月 - 2027年03月

    日本学術振興会  科学研究費助成事業  基盤研究(B)

    尾崎 敏文, 藤原 智洋, 近藤 彩奈, 長谷川 翼, 畑 利彰, 近藤 宏也, 杉原 進介, 吉田 晶

    　 詳細を見る

    配分額：17290000円 （ 直接経費：13300000円 、 間接経費：3990000円 ）

    骨軟部肉腫には有用な血中バイオマーカーに極めて乏しく、予後改善を妨げている。歴史的には、骨軟部肉腫の一部に特異的な融合遺伝子が発見されたことで組織診断の精度は向上したが、これまで血液を用いた非侵襲的な方法は開発されていなかった。本年度は、腫瘍分泌サイトカインの体液診断法への応用の可能性について検討を行った。本施設で手術治療を行った粘液線維肉腫(MFS)患者22名、未分化多形肉腫(UPS)患者20名における、治療前血清中サイトカインA濃度を健常人を対象に計測した。ヒトMFS細胞株(NMFH1)、ヒトUPS細胞株(NCC-UPS1-C1)からのサイトカインAの分泌を時間および細胞数依存的に解析した。また、MFS・UPS組織における腫瘍関連マクロファージ（TAM）の浸潤割合を解析した。UPS群、MFS群の血清中サイトカインA濃度は、それぞれ健常人に比べ有意に高値を示した（p<0.05）。MFS・UPS細胞株からのサイトカインA濃度は細胞数・培養時間依存的に上昇した。また、UPS群、MFS群におけるTAMは腫瘍組織において、それぞれ約20-30%の浸潤が確認された。以上の結果から、浸潤性軟部肉腫はサイトカインAを分泌し、血流にのって腫瘍微小環境にTAMを誘導している可能性が示唆された。TAMは悪性腫瘍での腫瘍微小環境において、血管新生や転移、抗アポトーシス効果などで腫瘍の増殖を加速させる因子となっている。血中サイトカインA測定により、TAM誘導の程度や腫瘍進展の可能性を予測し、TAMを標的とした治療選択に応用できる可能性があると考えられた。

    researchmap

  • 軟部肉腫における腫瘍由来液性因子に惹起される微小環境ネットワークの包括的解明

    研究課題/領域番号：22K07303  2022年04月 - 2025年03月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    畑 利彰, 藤原 智洋, 近藤 宏也, 吉田 晶

    　 詳細を見る

    配分額：4160000円 （ 直接経費：3200000円 、 間接経費：960000円 ）

    researchmap

  • 腫瘍免疫療法に主眼を置いた骨軟部肉腫に対する腫瘍融解ウイルスを用いた新規治療戦略

    研究課題/領域番号：19K23888  2019年08月 - 2022年03月

    日本学術振興会  科学研究費助成事業  研究活動スタート支援

    近藤 宏也

    　 詳細を見る

    配分額：2860000円 （ 直接経費：2200000円 、 間接経費：660000円 ）

    p53自体が免疫原性細胞死にかかわる事が知られていたが、実際にOBP-702でvivoモデルに対して腫瘍免疫活性を示すことができた。また、遠隔腫瘍に対するアブスコパル効果を示すことができ、局所治療であった腫瘍融解ウィルス製剤の原発巣と遠隔巣への同時治療への応用が期待される。また全身における免疫反応の活性化を介する抗腫瘍効果が期待できるため抗PD-1等の免疫チャックポイント阻害薬との併用療法等の応用の可能性も期待できる。近年注目されている免疫細胞を中心とした腫瘍周囲微小環境の変化も注目されており治療応用の可能性、研究テーマ拡大の可能性を残すものであり非常に有意義な研究結果であった。

    researchmap

その他研究活動

  • 日本がん治療認定医機構認定がん治療認定医

    2024年04月
    -
    現在

    　詳細を見る

  • 日本リハビリテーション学会認定リハビリテーション専門医

    2023年06月
    -
    現在

    　詳細を見る

  • 日本体育協会 認定スポーツドクター

    2022年07月
    -
    現在

    　詳細を見る

  • 日本整形外科専門医

    2021年03月
    -
    現在

    　詳細を見る

  • 日本整形外科学会 認定運動器リハビリテーション医

    2023年03月

    　詳細を見る